Skip Navigation
NIH HHS News Release Logo
National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Wednesday, Jan. 20, 2010

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

NIAID MEDIA AVAILABILITY
Identified: Switch that Turns On the
Allergic Response in People

WHAT:

A new study in human cells has singled out a molecule that specifically directs immune cells to develop the capability to produce an allergic response. The signaling molecule, called thymic stromal lymphopoietin (TSLP), is key to the development of allergic diseases such as asthma, atopic dermatitis (eczema), and food allergy.

The study team, led by Yong-Jun Liu, M.D., Ph.D., at the University of Texas M.D. Anderson Cancer Center, Houston, focused on dendritic cells, immune cells that initiate the primary immune response. Dendritic cells come into contact with other immune cells known as T cells, causing them to develop into different subsets of T cells, including helper 1 (Th1) and helper 2 (Th2) cells. These T-cell subsets are involved in protective immune responses, but the Th2 cells can also drive an allergic response. Until now, it was not known how dendritic cells induced T cells to become Th2 cells.

The investigators used dendritic cells isolated from the blood of healthy donors and found that the binding of TSLP to these cells activates a distinct set of signaling pathways within the cells. As a result, the dendritic cells produce messenger molecules that act on the T cells, causing them to develop into Th2 cells.

The study identifies TSLP as a switch that causes the development of the allergic response in people and suggests that this molecule may be a potential therapeutic target to treat and prevent allergic diseases.

Dr. Liu and his colleagues are supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The investigators are with the Asthma and Allergic Diseases Cooperative Research Centers program, now in its fourth decade of continuous funding as the cornerstone of NIAID’s asthma and allergy research portfolio.

ARTICLE: K Arima et al. Distinct signal codes generate dendritic cell functional plasticity. Science Signaling. DOI: 10.1126/scisignal.2000567 (2010).
WHO: Marshall Plaut, M.D., Chief, Allergic Mechanisms Section, Asthma, Allergy and Inflammation Branch, NIAID Division of Allergy, Immunology and Transplantation, is available to comment on this article.
CONTACT: To schedule interviews, please contact Julie Wu, 301-402-1663, niaidnews@niaid.nih.gov.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Last Updated January 20, 2010